Ubhi K, Masliah E. Alzheimer’s disease: recent advances and future perspectives [J]. J Alzheimers Dis, 2013, 33:S185-194.
[2]
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers [J]. Biochem Pharmacol, 2014, 88(4):640-651.
[3]
Chan K Y, Wang W, Wu J J, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis [J]. Lancet, 2013, 381(9882):2016-2023.
[4]
Dubois B, Feldman H H, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria [J]. Lancet Neurol, 2014, 13 (6):614-629.
[5]
Terry R D, Gonatas N K, Weiss M. Ultrastructural studies in alzheimer’s presenile dementia [J]. Am J Pathol, 1964, 44:269-297.
[6]
Glenner G G, Wong C W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein [J]. Biochem Biophys Res Commun, 1984, 120(3):885-890.
[7]
Hardy J A, Higgins G A. Alzheimer’s disease: the amyloid cascade hypothesis [J]. Science, 1992, 256(5054):184-185.
[8]
Kung H F. The β-Amyloid hypothesis in Alzheimer’s disease seeing is believing [J]. ACS Med Chem Lett, 2012, 3(4):265-267.
[9]
McLean C A, Cherny R A, Fraser F W, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease [J]. Ann Neurol, 1999, 46(6):860-866.
[10]
Klein W L, Krafft G A, Finch C E. Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum?[J].Trends Neurosci, 2001, 24(4):219-224.
[11]
Morris E,Chalkidou A,Hammers A, et al. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis [J]. Eur J Nucl Med Mol Imaging, 2016, 43(2):374-385.
[12]
Agdeppa E D, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease [J]. J Neurosci, 2001, 21(24): 189.
[13]
Shoghi-Jadid K, Small G W, Agdeppa E D, et al. Localization of neurofibrillary tangles and betaamyloid plaques in the brains of living patients with Alzheimer disease [J]. Am J Geriatr Psychiatry, 2002, 10(1): 24-35.
[14]
Mathis C A, Bacskai B J, Kajdasz S T, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain [J]. Bioorg Med Chem Lett, 2002, 12(3):295-298.
[15]
Klunk W E, Wang Y, Huang G F, et al. The binding of 2-(4’-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component [J]. J Neurosci, 2003, 23(6):2086-2092.
[16]
Klunk W E, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B [J]. Ann Neurol, 2004, 55(3):306-319.
[17]
Ng S, Villemagne V L, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease [J]. J Nucl Med, 2007, 48(4):547-552.
Villemagne V L, Pike K E, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease [J]. Ann Neurol, 2011, 69(1):181-192.
[20]
Nordberg A. Amyloid imaging in Alzheimer’s disease [J]. Curr Opin Neurol, 2007, 20 (4): 398-402.
[21]
Pike K E, Savage G, Villemagne V L, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease [J]. Brain, 2007, 130(11):2837-2844.
[22]
Villemagne V L, Pike K E, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease [J]. Neuropsychologia, 2008, 46(6):1688-1697.
[23]
Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study [J]. Neurology, 2009, 73(10):754-760.
[24]
Rowe C C, Ellis K A, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging [J]. Neurobiol Aging, 2010, 31(8):1275-1283.
[25]
Ikonomovic M D,Buckley C J,Heurling K, et al. Post-mortem histopatho-logy underlying β-amyloid PET imaging following flutemetamol F 18 injection [J]. Acta Neuropathol Commun, 2016, 4(1):130.
[26]
Miki T,Shimada H,Kim J S, et al. Brain uptake and safety of Flutemeta-mol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subje-cts with amnestic mild cognitive impairment and healthy volunteers [J]. Ann N-ucl Med, 2017, 31(3):260-272.
[27]
Wong D F, Rosenberg P B, Zhou Y, et al. In vivo imaging of amyloid de-position in Alzheimer disease using the radiolig and 18F-AV-45 (florbetapir[c-orrected] F 18) [J]. J Nucl Med, 2010, 51(6): 913-920.
[28]
Wolk D A, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer’s disease:comparison of florbetapir and Pittsburgh compound-B positron emission tomography [J].J Neurol Neurosurg Psychiatry, 2012, 83(9): 923-926.
[29]
Kingwell K. Alzheimer disease: Florbetapir-a useful tool to image amyloid load and predict cognitive decline in Alzheimer disease [J].Nat Rev Neurol, 2012, 8(9): 471.
[30]
Camus V, Payoux P, Barre L, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment [J]. Eur J Nucl Med Mol Imaging, 2012, 39(4):621-631.
[31]
Hauser S L, Josephson S A, Johnston S C. Florbetapir: knowing one’s future [J]. Ann Neurol, 2012, 71(6): A6.
2018, Vol. 29 
